CARDIOVASCULAR DRUGS AND THERAPY

Scope & Guideline

Uncovering the latest in cardiovascular drug advancements.

Introduction

Immerse yourself in the scholarly insights of CARDIOVASCULAR DRUGS AND THERAPY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0920-3206
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1987 to 2024
AbbreviationCARDIOVASC DRUG THER / Cardiovasc. Drugs Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal "Cardiovascular Drugs and Therapy" focuses on the pharmacological aspects of cardiovascular diseases and therapies, emphasizing the efficacy, safety, and mechanisms of various cardiovascular drugs. It serves as a critical platform for disseminating research findings that explore drug interactions, treatment outcomes, and innovative therapeutic strategies in the field of cardiovascular medicine.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal discusses various pharmacological treatments for cardiovascular diseases, including antiplatelet agents, anticoagulants, lipid-lowering drugs, and antihypertensives, analyzing their efficacy, safety, and clinical implications.
  2. Clinical Trials and Meta-analyses:
    It publishes results from clinical trials and meta-analyses that evaluate the effectiveness of new and existing cardiovascular therapies, providing evidence-based insights for clinicians and researchers.
  3. Mechanisms of Cardiovascular Drugs:
    Research on the underlying mechanisms of action of cardiovascular drugs is a focus area, exploring how these drugs interact at the molecular and cellular levels to influence cardiovascular health.
  4. Innovative Therapeutic Strategies:
    The journal highlights novel approaches to cardiovascular treatment, including the development of new drug formulations, combination therapies, and the use of genetic and biomarker information to tailor treatments.
  5. Real-World Evidence and Pharmacovigilance:
    It emphasizes the importance of real-world data and pharmacovigilance studies in understanding the long-term safety and effectiveness of cardiovascular therapies, informing clinical practice.
The journal "Cardiovascular Drugs and Therapy" has identified several emerging trends and themes that reflect the evolving landscape of cardiovascular research and therapy. These topics are gaining traction and are likely to shape future research directions.
  1. Precision Medicine in Cardiovascular Therapy:
    There is a growing focus on precision medicine approaches, including pharmacogenomics, that tailor cardiovascular treatments based on individual genetic and molecular profiles to enhance efficacy and safety.
  2. Role of SGLT2 Inhibitors:
    SGLT2 inhibitors have become a significant area of research, with numerous studies exploring their cardiovascular benefits beyond glycemic control, particularly in heart failure and renal protection.
  3. Anticoagulation Strategies in Atrial Fibrillation:
    Research into optimizing anticoagulation strategies for atrial fibrillation patients is trending, particularly regarding the comparative effectiveness of direct oral anticoagulants versus traditional therapies.
  4. Cardiovascular Impacts of Diabetes Medications:
    The intersection of diabetes management and cardiovascular health is increasingly prominent, with studies examining the cardiovascular effects of GLP-1 receptor agonists and other diabetes medications.
  5. Long-term Outcomes of Cardiovascular Interventions:
    There is an emerging emphasis on the long-term outcomes of various cardiovascular interventions, including surgical and catheter-based procedures, highlighting the importance of sustained patient follow-up.

Declining or Waning

While many areas continue to thrive, certain themes in the journal "Cardiovascular Drugs and Therapy" have shown a declining interest or frequency of publication. These waning scopes may reflect shifts in research priorities or advancements in the field that have rendered some topics less relevant.
  1. Traditional Antihypertensive Therapies:
    There appears to be a reduction in studies focusing solely on traditional antihypertensive medications, as newer classes of drugs and combination therapies gain prominence in clinical practice.
  2. Single-Agent Studies:
    Research focused exclusively on single-agent therapies is declining, with a noticeable shift towards combination therapies and multi-drug regimens that reflect contemporary clinical practice.
  3. Pharmacokinetics of Established Drugs:
    There is less emphasis on the pharmacokinetics of well-established cardiovascular drugs, as research increasingly prioritizes new therapeutic agents and innovative treatment strategies.
  4. Animal Model Studies:
    The prevalence of studies using traditional animal models to evaluate drug efficacy is decreasing, potentially due to a growing focus on human clinical trials and translational research.
  5. Generalized Risk Factor Studies:
    Research that broadly addresses cardiovascular risk factors without a direct link to specific therapeutic interventions is diminishing, as the emphasis shifts towards targeted therapeutic approaches.

Similar Journals

INVESTIGATIONAL NEW DRUGS

Elevating Therapeutic Strategies Through Rigorous Research
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Cardiovascular Diagnosis and Therapy

Transforming Cardiovascular Health with Cutting-Edge Discoveries
Publisher: AME PUBLISHING COMPANYISSN: 2223-3652Frequency: 6 issues/year

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

Journal of the American Heart Association

Empowering Cardiologists with Cutting-Edge Discoveries
Publisher: WILEYISSN: Frequency: 24 issues/year

The Journal of the American Heart Association, published by WILEY, serves as a premier platform for advancing cardiovascular medicine through its commitment to open access, fostering global dissemination of cutting-edge research since 2012. It proudly holds a prestigious position within the top quartile (Q1) in the categories of Cardiology and Cardiovascular Medicine, as evidenced by its Scopus ranking of #49 out of 387 journals, placing it in the 87th percentile. With a focus on innovative studies and transformative findings, this journal is essential for cardiologists, researchers, and healthcare professionals seeking to stay at the forefront of cardiovascular knowledge. The journal aims to bridge the gap between basic science and clinical practice, presenting findings that shape the future of heart health treatment and prevention. As a resource for academic and clinical communities alike, the Journal of the American Heart Association is dedicated to enhancing the understanding and treatment of cardiovascular diseases globally.

Current Vascular Pharmacology

Shaping the Future of Cardiovascular Pharmacological Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1611Frequency: 6 issues/year

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

Cardiovascular Endocrinology & Metabolism

Innovating Research at the Intersection of Cardiology and Endocrinology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2574-0954Frequency: 4 issues/year

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

International Journal of Cardiology

Exploring New Frontiers in Heart Disease Understanding
Publisher: ELSEVIER IRELAND LTDISSN: 0167-5273Frequency: 24 issues/year

The International Journal of Cardiology is a premier publication in the field of Cardiology and Cardiovascular Medicine, published by Elsevier Ireland Ltd. With an impressive impact factor and ranked in the top quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and scholars committed to advancing cardiovascular health. Founded in 1981, the journal has been pivotal in disseminating significant findings, with a wide-ranging scope that includes original research, reviews, and clinical studies aimed at improving patient outcomes and understanding heart diseases. Its robust ranking of #73 out of 387 in Scopus ensures that it remains a leading platform for impactful cardiovascular research. While currently not an open-access publication, the journal's commitment to quality and relevance makes it an essential reference point within an ever-evolving medical landscape. For those engaged in cardiovascular research, the International Journal of Cardiology is not just a journal; it's an indispensable source of knowledge shaping the future of heart health.

Archives of Cardiovascular Diseases

Advancing cardiovascular health through groundbreaking research.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 1875-2136Frequency: 12 issues/year

The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.

EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transforming Insights into Innovations
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-3784Frequency: 12 issues/year

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

COR ET VASA

Elevating cardiovascular discourse in the European community.
Publisher: CZECH SOC CARDIOLOGY & CZECH SOC CARDIOVASCULAR SURGERYISSN: 0010-8650Frequency: 6 issues/year

COR ET VASA is a prominent peer-reviewed journal in the field of cardiology and cardiovascular medicine, published by the Czech Society of Cardiology and Czech Society of Cardiovascular Surgery. Established in 1961, and continuing its legacy from 2006 to 2024, this journal serves as an essential platform for disseminating significant research findings, clinical studies, and innovative treatments in cardiovascular health. While currently positioned in the Q4 quartile, the journal aims to enhance its impact by fostering knowledge sharing among researchers, clinicians, and students alike. The journal, with its publication in Czech Republic, provides a unique perspective to the European cardiovascular community, allowing for invaluable insights and discourse. Researchers are encouraged to submit their manuscripts and contribute to the growing body of knowledge in this critical area, although it should be noted that COR ET VASA does not offer open access options at this time. As the field of cardiovascular medicine evolves, COR ET VASA remains committed to addressing the latest challenges and advancements, nurturing a rich dialogue within the community.

Anatolian Journal of Cardiology

Fostering Cardiovascular Excellence Since 2001.
Publisher: KARE PUBLISSN: 2149-2263Frequency: 12 issues/year

The Anatolian Journal of Cardiology, published by KARE PUBL, stands as a vital resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 2149-2263 and E-ISSN 2149-2271, this Open Access journal has been fostering the dissemination of critical research since 2001, ensuring that high-quality content is freely available to a global audience. Based in Turkey, the journal aims to bridge gaps in cardiological knowledge through rigorous peer-reviewed articles that span a wide range of topics, from innovative clinical practices to groundbreaking research findings. While its current ranking places it in the Q3 category of cardiology journals, the Anatolian Journal of Cardiology continues to strive towards enhancing its impact, currently holding a Scopus rank of 236 out of 387. Researchers, practitioners, and students alike will find this journal an essential platform for keeping abreast of the latest developments in cardiovascular health.